Innotox (nivobotulinumtoxinA) / Medytox, AbbVie - LARVOL DELTA

Thermal Stability of Botulinum Toxin Type A Formulations Exposed to Heat In Vitro, Assessed by an In Vivo Mouse Potency Bioassay. (PubMed, Aesthet Surg J Open Forum) - "This study investigated the thermal stability of 4 commercial botulinum toxin type A (BoNT/A) products under conditions simulating EBD-related heat exposure, which includes 1 liquid formulation (INNOTOX, Medytox, Seoul, South Korea; hereafter referred to as innoBoNT/A) and 3 powder formulations: onabotulinumtoxinA (onaBoNT/A, BOTOX, Allergan, an Abbvie company, North Chicago, IL), incobotulinumtoxinA (incoBoNT/A, XEOMIN, Merz, Frankfurt, Germany), and abobotulinumtoxinA (aboBoNT/A, DYSPORT, Ipsen, Boulogne-Billancourt, France). In particular, onaBoNT/A showed a 32% decrease upon exposure at 60°C for 25 min and a complete loss of measurable potency at when exposed at 60°C for 40 min. Among the BoNT/A formulations evaluated, only the liquid-stabilized preparation preserved potency during thermal stress."

Journal • Preclinical

Korean botulinum toxins. (PubMed, J Neural Transm (Vienna)) - "These are PrabotulinumtoxinA (Daewoong/Evolus) and LetibotulinumtoxinA (Hugel/Croma Pharma). There are 12 Class 2 drugs from 10 Korean manufacturers registered in Korea for export and domestic use, including Neuronox®, the first Korean BT drug registered in 2006, NivobotulinumtoxinA/Innotox®, the world-wide first liquid BT type A preparation and Coretox®, the world-wide second BT drug without complexing proteins...5 Korean manufacturers have 5 drug projects in Korea in advanced development phases. With this, Korea is now the country with the worldwide largest number of BT manufacturers and BT drugs."

Journal

NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines. (PubMed, Dermatol Surg) - "Liquid nivobotulinumtoxinA was effective and well-tolerated for treating moderate-to-severe LCL with/without GL."

Clinical • Journal • Aesthetic Medicine • Pain

Nanomaterials and security in occupational and forensic medicine: insights from nanotoxicology. (PubMed, Front Toxicol) - "Problems related to exposure to nanonenergetics can therefore potentially affect both exposed workers (both in the production and use phase) and the civilian population, if used in war scenarios, for example,. Starting from these assumptions, the INNOTOX research project aims to contribute to the in-depth study of the toxicity of nanonenergetics, through an integrated approach involving experts in occupational and forensic medicine, nanotoxicology and bioengineering."

Journal

NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. (PubMed, Aesthet Surg J) - "Liquid nivobotulinumtoxinA was effective and well tolerated for treating moderate-to-severe GL alone or with LCL."

Journal • P3 data • Aesthetic Medicine

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (clinicaltrials.gov) - P3 | N=958 | Completed | Sponsor: Medy-Tox | Active, not recruiting ➔ Completed

Trial completion

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (clinicaltrials.gov) - P3; N=800; Active, not recruiting; Sponsor: Allergan; Enrolling by invitation ➔ Active, not recruiting

Clinical • Enrollment closed